AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival

AbbVie Inc. and Enanta Pharmaceuticals Inc.’s hepatitis C combination drug will be about 12 percent cheaper than its rival from Gilead Sciences Inc., setting the stage for fierce competition for patients of the liver virus.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.